Barclays raised the firm’s price target on Zimmer Biomet to $130 from $120 and keeps an Underweight rating on the shares post the Q4 report. The analyst says the company set an “ambitious” 5%-6% bar for sales growth in 202 despite slower than expected Q4 growth in U.S. Ortho. The firm remains concerned about Zimmer’s ability to deliver sustainable growth at or above market growth rated in Hips, Knees and Shoulder reconstruction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZBH:
- Zimmer Biomet price target lowered to $140 from $147 at Deutsche Bank
- Zimmer Biomet price target raised to $132 from $119 at Wells Fargo
- Citi opens ‘positive catalyst watch’ on Zimmer Biomet into AAOS
- Zimmer Biomet price target raised to $155 from $149 at Baird
- Zimmer Biomet sees FY24 adjusted EPS $8.00-$8.15, consensus $7.94
